Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study

Lisha Li, Yingyang Xu, Sainan Bian, Zhouxian Pan, Kai Guan

Open source

DOI
10.1016/j.waojou.2026.101394
Published
2026-07
Container
World Allergy Organization Journal
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.waojou.2026.101394,
  title = {Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study},
  author = {Lisha Li and Yingyang Xu and Sainan Bian and Zhouxian Pan and Kai Guan},
  year = {2026},
  journal = {World Allergy Organization Journal},
  doi = {10.1016/j.waojou.2026.101394},
  url = {https://doi.org/10.1016/j.waojou.2026.101394}
}

RIS

TY  - JOUR
TI  - Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study
AU  - Lisha Li
AU  - Yingyang Xu
AU  - Sainan Bian
AU  - Zhouxian Pan
AU  - Kai Guan
PY  - 2026
JO  - World Allergy Organization Journal
DO  - 10.1016/j.waojou.2026.101394
UR  - https://doi.org/10.1016/j.waojou.2026.101394
ER  - 

APA

Li, L., Xu, Y., Bian, S., Pan, Z., & Guan, K. (2026). Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study. World Allergy Organization Journal. https://doi.org/10.1016/j.waojou.2026.101394

Source records